digital currency symbols, Knowledge graph

Guoxin Technology: shareholders such as the National Fund intend to reduce their holdings by no more than 3%;Say a data, since 2010, A shares have opened higher by more than 2% for 13 times, including 11 times of high opening and low walking, and only 2 times of high opening and high walking! Just get used to it, this is the urine of big A. Actually, it was good yesterday, which was in line with the slow cow. It is estimated that some people are still breathing a sigh of relief. If it rises like the beginning of October, they will not be able to sleep! You know, yesterday was a slow cow.Contemporary Amperex Technology Co., Limited, as the king of volume, stopped making money everywhere and began to repay investors! Other domestic new energy giants can learn from it. Yesterday, Ning Wang opened higher and lower, and took the GEM with a bias. In the evening, the two big benefits were blessed. Can today's surge drive the GEM to rise?

Recently, all localities are vigorously promoting mergers and acquisitions, first in Shenzhen and then in Shanghai, and it is estimated that Beijing will soon. The listed companies in the north and Shenzhen are all active, and the merger of Shanghai benchmark brokerage Haitong+Guotai Junan has landed! Other places will follow suit, but mergers and acquisitions are really difficult to grasp, and it is estimated that there are more local+state-owned assets.Wentai Technology: Shareholders plan to reduce their holdings by no more than 2%;True Vision: The controlling shareholder and others intend to reduce their holdings by 4% in total;

Haineng Industry: The controlling shareholder intends to reduce the company's shares by no more than 3%;First, heavy! Shanghai merger and reorganization action plan announcedAmong them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.